Table 2.
Numbers and percentages screened, eligible, approached and randomised,16 shown by site across 28 sites activated and totals.
| Site ID | N screened | Eligible (of those screened)b | Approached (of those eligible)c | Doctor/patient uncertain (of those approached) | Consented (of those doctor & patient uncertain) | Randomised (of those eligible) | Randomised (of those approached)d |
|---|---|---|---|---|---|---|---|
| 11 | 37 | 30 (81%) | 18 (60%) | 5 (28%) | 4 (80%) | 4 (13%) | 4 (22%) |
| 13 | 4 | 2 (50%) | 2 (100%) | 1 (50%) | 1 (100%) | 1 (50%) | 1 (50%) |
| 14 (P) | 7 | 5 (71%) | 2 (40%) | 0 (0%) | 0 (0.0%) | 0 (0%) | 0 (0%) |
| 15 | 37 | 28 (76%) | 24 (86%) | 6 (25%) | 2 (33%) | 2 (7%) | 2 (8%) |
| 16 | 49 | 25 (51%) | 17 (68%) | 16 (94%) | 12 (75%) | 12 (48%) | 12 (71%) |
| 17 | 18 | 17 (94%) | 11 (65%) | 2 (18%) | 1 (50%) | 1 (6%) | 1 (9%) |
| 18 (P) | 10 | 4 (40%) | 2 (50%) | 1 (50%) | 1 (100%) | 1 (25%) | 1 (50%) |
| 19 | 14 | 9 (64%) | 7 (78%) | 5 (71%) | 5 (100%) | 4 (44%) | 4 (57%) |
| 22a | 1 | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) |
| 23 (P) | 7 | 3 (43%) | 1 (33%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| 25 | 3 | 3 (100%) | 3 (100%) | 2 (67%) | 2 (100%) | 2 (67%) | 2 (67%) |
| 26 (P) | 2 | 2 (100%) | 2 (100%) | 2 (100%) | 2 (100%) | 2 (100%) | 2 (100%) |
| 27 | 11 | 9 (82%) | 8 (89%) | 3 (38%) | 3 (100%) | 3 (33%) | 3 (38%) |
| 30 | 21 | 20 (95%) | 20 (100%) | 10 (50%) | 8 (80%) | 8 (40%) | 8 (40%) |
| 31a | 0 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0.0%) | 0 (0.0%) | 0 (0%) |
| 33 | 1 | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) |
| 34 | 72 | 24 (33%) | 7 (29%) | 1 (14%) | 1 (100%) | 1 (4%) | 1 (14%) |
| 35 | 68 | 48 (71%) | 16 (33%) | 6 (38%) | 3 (50%) | 3 (6%) | 3 (19%) |
| 36a | 1 | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) |
| 37 | 7 | 3 (43%) | 1 (33%) | 1 (100%) | 1 (100%) | 1 (33%) | 1 (100%) |
| 38 (P) | 1 | 1 (100%) | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| 39 | 36 | 25 (69%) | 24 (96%) | 15 (63%) | 13 (87%) | 13 (52%) | 13 (54%) |
| 40 | 0 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0.0%) | 0 (0.0%) | 0 (0%) |
| 44 | 35 | 28 (80%) | 5 (18%) | 2 (40%) | 2 (100%) | 2 (7%) | 2 (40%) |
| 45 | 38 | 7 (18%) | 2 (29%) | 1 (50%) | 1 (100%) | 1 (14%) | 1 (50%) |
| 46 (P)a | 3 | 2 (67%) | 2 (100%) | 1 (50%) | 1 (100%) | 1 (50%) | 1 (50%) |
| 47 | 27 | 23 (85%) | 23 (100%) | 11 (48%) | 7 (64%) | 7 (30%) | 7 (30%) |
| 48 | 1 | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0.0%) | 0 (0%) | 0 (0%) |
| ALL SITES | 511 | 322 (63%) | 202 (63%) | 96 (48%) | 73 (76%) | 72 (22%) | 72 (36%) |
(P), paediatric only site where screened numbers were likely to be lower.
a
Site activated during final 6 mnths of recruitment.
b
Low proportions indicated highly inclusive approach to screening or problematic exclusion of potentially eligible patients.
c
Low proportions indicated decision not to approach people with symptomatic brain cavernoma.
d
Low proportions indicated potential difficulties discussing the trial. All above needed further investigation via qualitative data collection.